
In a randomized trial comparing electroconvulsive therapy (ECT) and subanesthetic intravenous ketamine for treatment-resistant major depression, the study found that ketamine was non-inferior to ECT. The trial involved 403 patients who were assigned to receive either ketamine or ECT. After the treatment phase, 55.4% of patients in the ketamine group and 41.2% in the ECT group showed a response to treatment. ECT was associated with a temporary decrease in memory recall, while ketamine was linked to dissociation. Patient-reported quality of life improved similarly in both groups. These findings suggest ketamine may be a viable alternative to ECT for treatment-resistant major depression without psychosis.
Like
Save
Share